Related Experiment Videos
Impact of imipenem/cilastatin therapy on normal fecal flora
Abstract:
The impact of parenteral imipenem/cilastatin therapy on the bowel flora of six patients was evaluated. Stool samples were collected before and during therapy and qualitative and quantitative bacteriologic studies were performed. Imipenem had no effect on total microorganism counts. Two patients acquired Candida albicans during therapy, and three patients acquired Proteus species. Pseudomonas species in one patient acquired resistance. Imipenem appears to have a relatively modest effect on the bowel flora and apparently does not readily induce resistance in the resident flora as compared with other agents.
Insights
Parenteral imipenem/cilastatin therapy showed a modest impact on bowel flora in six patients. While some acquired new microbes like Candida and Proteus, resistance was not readily induced compared to other antibiotics.
Area of Science:
- Microbiology
- Pharmacology
- Gastroenterology
Background:
- Antibiotic therapy can significantly alter the gut microbiome.
- Understanding the impact of specific antibiotics on bowel flora is crucial for patient management and preventing dysbiosis.
Purpose of the Study:
- To evaluate the effect of parenteral imipenem/cilastatin on the intestinal microbial composition.
- To assess the potential for imipenem/cilastatin to induce resistance in bowel flora.
Main Methods:
- Qualitative and quantitative bacteriologic analysis of stool samples.
- Samples were collected from six patients before and during imipenem/cilastatin treatment.
Main Results:
- No significant change in total microorganism counts was observed.
- Two patients showed acquisition of Candida albicans; three acquired Proteus species.
- One patient developed resistance in Pseudomonas species.
Conclusions:
- Parenteral imipenem/cilastatin has a relatively modest impact on bowel flora.
- It does not appear to readily induce resistance in the resident gut microbiota compared to other antimicrobial agents.